Tu Van Dao

Nhà nghiên cứu Hồ sơ 6/10

63 công bố · 3.001 trích dẫn · h-index 13

Thông tin

🏛️Nơi công tác: Trường Đại học Y Hà Nội
🔬Lĩnh vực: Y - Dược
🆔ORCID: 0000-0001-6858-8347
✍️Hồ sơ chưa đầy đủ — bổ sung thông tin

Chỉ số h-index 13 xếp học giả này vào lĩnh vực Y - Dược, thuộc nhóm 10% dẫn đầu trong 6.619 hồ sơ cùng lĩnh vực của danh bạ này.

Công bố tiêu biểu

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma1,495 trích dẫn
NEJM Evidence · 2022 · DOI

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.404 trích dẫn
Journal of Clinical Oncology · 2022 · DOI

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma329 trích dẫn
Annals of Oncology · 2024 · DOI

Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC142 trích dẫn
Journal of Hepatology · 2025 · DOI

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)54 trích dẫn
Journal of Clinical Oncology · 2022 · DOI

Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma41 trích dẫn
Journal of Hepatology · 2024 · DOI

Ubiquitin carboxyl-terminal esterase L1 (UCHL1) is associated with stem-like cancer cell functions in pediatric high-grade glioma35 trích dẫn
PLoS ONE · 2017 · DOI

Intensive quadratic programming approach for home energy management systems with power utility requirements26 trích dẫn
International Journal of Electrical Power & Energy Systems · 2019 · DOI

BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).26 trích dẫn
Journal of Clinical Oncology · 2022 · DOI

947MO Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)25 trích dẫn
Annals of Oncology · 2024 · DOI

Về lĩnh vực Y - Dược

6.619học giả

91.896công bố

2.589.484trích dẫn

4.2h-index trung bình

Hướng nghiên cứu phổ biến trong lĩnh vực:

Mosquito-borne diseases and controlAntibiotic Resistance in BacteriaTuberculosis Research and EpidemiologyMalaria Research and ControlCOVID-19 and Mental HealthHIV/AIDS Research and Interventions

Nơi có nhiều học giả lĩnh vực này nhất: